Guide to Diagnostic Tests
Streptococcus pneumoniae, resistant
To view the entire topic, please log in or purchase a subscription.
Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Explore these free sample topics:
-- The first section of this topic is shown below --
Organism
Streptococcus pneumoniae, resistant
Streptococcus pneumoniae is a gram-positive diplococcus that was generally susceptible to all classes of antimicrobial agents in the 1970s.
With increased usage of antibiotics in patients with viral infections, S. pneumoniae has acquired genetic material that encodes resistance to many commonly used antibiotics.
It has developed resistance to beta-lactamases (45%) at altered penicillin-binding protein sites, to macrolides (40%) with a macrolide efflux pump ( mef genes) and erythromycin-ribosomal methylases ( erm genes) sites, to lincosamines (14%), to tetracycline, to folate-inhibitors (14–21%), and to fluoroquinolones (1–2%) with mutations in genes that code for DNA gyrase and topoisomerase IV sites. Emergence of the multidrug-resistant S. pneumoniae serotype 19A is due in part to routine use of protein-conjugated pneumococcal vaccine in the US, since this serotype is not included in the vaccine.
-- To view the remaining sections of this topic, please log in or purchase a subscription --
Organism
Streptococcus pneumoniae, resistant
Streptococcus pneumoniae is a gram-positive diplococcus that was generally susceptible to all classes of antimicrobial agents in the 1970s.
With increased usage of antibiotics in patients with viral infections, S. pneumoniae has acquired genetic material that encodes resistance to many commonly used antibiotics.
It has developed resistance to beta-lactamases (45%) at altered penicillin-binding protein sites, to macrolides (40%) with a macrolide efflux pump ( mef genes) and erythromycin-ribosomal methylases ( erm genes) sites, to lincosamines (14%), to tetracycline, to folate-inhibitors (14–21%), and to fluoroquinolones (1–2%) with mutations in genes that code for DNA gyrase and topoisomerase IV sites. Emergence of the multidrug-resistant S. pneumoniae serotype 19A is due in part to routine use of protein-conjugated pneumococcal vaccine in the US, since this serotype is not included in the vaccine.
There's more to see -- the rest of this topic is available only to subscribers.
